Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer.
ovarian cancer
prognostic and predictive role
tumor immunology
tumor microenvironment
tumor-infiltrating lymphocytes (TILs)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Sep 2022
06 Sep 2022
Historique:
received:
19
08
2022
revised:
02
09
2022
accepted:
02
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
In the last decade, tumor-infiltrating lymphocytes (TILs) have been recognized as clinically relevant prognostic markers for improved survival, providing the immunological basis for the development of new therapeutic strategies and showing a significant prognostic and predictive role in several malignancies, including ovarian cancer (OC). In fact, many OCs show TILs whose typology and degree of infiltration have been shown to be strongly correlated with prognosis and survival. The OC histological subtype with the higher presence of TILs is the high-grade serous carcinoma (HGSC) followed by the endometrioid subtype, whereas mucinous and clear cell OCs seem to contain a lower percentage of TILs. The abundant presence of TILs in OC suggests an immunogenic potential for this tumor. Despite the high immunogenic potential, OC has been described as a highly immunosuppressive tumor with a high expression of PD1 by TILs. Although further studies are needed to better define their role in prognostic stratification and the therapeutic implication, intraepithelial TILs represent a relevant prognostic factor to take into account in OC. In this review, we will discuss the promising role of TILs as markers which are able to reflect the anticancer immune response, describing their potential capability to predict prognosis and therapy response in OC.
Identifiants
pubmed: 36139508
pii: cancers14184344
doi: 10.3390/cancers14184344
pmc: PMC9497073
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cancer Metastasis Rev. 2012 Jun;31(1-2):143-62
pubmed: 22101807
Oncoimmunology. 2012 Nov 1;1(8):1223-1225
pubmed: 23243584
Cancer Sci. 2007 Mar;98(3):455-63
pubmed: 17233811
Eur J Cancer. 2013 Jan;49(2):520-30
pubmed: 22897840
BMC Cancer. 2017 Sep 20;17(1):657
pubmed: 28931370
Gynecol Oncol. 2008 Feb;108(2):415-20
pubmed: 18037158
J Leukoc Biol. 2011 Jan;89(1):31-9
pubmed: 20628066
Oncotarget. 2016 Mar 22;7(12):13587-98
pubmed: 26871470
J Immunol. 2007 Jun 1;178(11):6730-3
pubmed: 17513719
Front Oncol. 2020 Apr 28;10:570
pubmed: 32457830
Cancers (Basel). 2021 Dec 11;13(24):
pubmed: 34944851
Curr Treat Options Oncol. 2018 Nov 14;19(12):74
pubmed: 30430276
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Front Mol Biosci. 2020 Jan 31;6:160
pubmed: 32118030
Oncotarget. 2016 Jan 12;7(2):1486-99
pubmed: 26625204
Am J Reprod Immunol. 2005 Dec;54(6):369-77
pubmed: 16305662
BMC Genomics. 2017 Mar 21;18(1):243
pubmed: 28327095
Crit Rev Oncol Hematol. 2022 Feb;170:103597
pubmed: 35033663
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Clin Chim Acta. 2018 Jul;482:27-32
pubmed: 29572186
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708
ESMO Open. 2021 Aug;6(4):100235
pubmed: 34371384
Clin Cancer Res. 2016 Jun 15;22(12):3025-36
pubmed: 27306793
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Gynecol Oncol Rep. 2019 Jun 18;29:48-54
pubmed: 31312712
Cancer Metastasis Rev. 2011 Mar;30(1):141-51
pubmed: 21298574
Front Oncol. 2021 Dec 13;11:795547
pubmed: 34966689
BMC Genomics. 2022 Jan 13;23(1):51
pubmed: 35026984
J Immunother Cancer. 2015 Mar 24;3:7
pubmed: 25806106
Front Immunol. 2021 May 27;12:656364
pubmed: 34122412
Cell. 2018 Aug 23;174(5):1293-1308.e36
pubmed: 29961579
Curr Opin Immunol. 2014 Apr;27:8-15
pubmed: 24487185
Int J Mol Sci. 2016 Dec 15;17(12):
pubmed: 27983698
Blood. 2009 Jul 9;114(2):357-9
pubmed: 19289853
Clin Cancer Res. 2016 Feb 1;22(3):714-24
pubmed: 26384738
Lancet. 2019 Mar 23;393(10177):1240-1253
pubmed: 30910306
J Clin Oncol. 2011 Mar 1;29(7):925-33
pubmed: 21079136
Am J Clin Pathol. 2006 Mar;125(3):451-8
pubmed: 16613351
PLoS One. 2014 Jan 07;9(1):e84941
pubmed: 24409314
Nat Med. 2014 Jun;20(6):607-15
pubmed: 24793239
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
J Exp Med. 2010 Mar 15;207(3):505-20
pubmed: 20176801
Medicina (Kaunas). 2021 Nov 29;57(12):
pubmed: 34946254
Curr Mol Med. 2009 Sep;9(7):836-50
pubmed: 19860663
Gene. 2006 Jan 17;366(1):2-16
pubmed: 16377102
Cancer Immunol Immunother. 2015 Dec;64(12):1495-504
pubmed: 26298430
Gynecol Oncol. 2016 May;141(2):293-302
pubmed: 26972336
J Cancer. 2017 Aug 25;8(15):2915-2923
pubmed: 28928882
J Ovarian Res. 2018 May 30;11(1):43
pubmed: 29843813
Cancer Res. 2012 Mar 1;72(5):1070-80
pubmed: 22266112
Gynecol Oncol. 2010 May;117(2):366-72
pubmed: 20144842
Cancer Res. 2010 Aug 1;70(15):6171-80
pubmed: 20631075
Oncogene. 2008 Oct 6;27(45):5904-12
pubmed: 18836471
Cancers (Basel). 2020 May 05;12(5):
pubmed: 32380732
J Immunol. 2007 Feb 1;178(3):1505-11
pubmed: 17237399
J Gynecol Oncol. 2017 Sep;28(5):e64
pubmed: 28657225
Gynecol Oncol Rep. 2022 Jan 07;39:100926
pubmed: 35146104
J Egypt Natl Canc Inst. 2021 Jul 9;33(1):16
pubmed: 34241710
Clin Cancer Res. 2005 Dec 1;11(23):8326-31
pubmed: 16322292
Oncotarget. 2020 Jun 02;11(22):2092-2105
pubmed: 32547707
Nature. 2013 Mar 14;495(7440):241-5
pubmed: 23467088
Ann Oncol. 2020 Aug;31(8):1030-1039
pubmed: 32339648
Chin Clin Oncol. 2020 Aug;9(4):47
pubmed: 32648448
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Mod Pathol. 2012 May;25(5):740-50
pubmed: 22282309
Cancer Biol Ther. 2015;16(6):807-20
pubmed: 25894333
Front Oncol. 2021 Feb 25;11:590414
pubmed: 33718143
Clin Cancer Res. 2017 Feb 15;23(4):925-934
pubmed: 27601594
Eur J Cancer. 2005 Nov;41(16):2502-12
pubmed: 16199153
Nat Rev Immunol. 2011 Sep 23;11(10):702-11
pubmed: 21941296
J Pathol. 2015 Jul;236(3):272-7
pubmed: 25810134
Clin Cancer Res. 2007 Jul 1;13(13):3951-9
pubmed: 17606729
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Cancer Discov. 2015 Jan;5(1):43-51
pubmed: 25358689
Gynecol Oncol. 2016 Oct;143(1):120-127
pubmed: 27470997
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Asian Pac J Cancer Prev. 2015;16(9):3635-8
pubmed: 25987014
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Annu Rev Immunol. 2011;29:235-71
pubmed: 21219185
J Thorac Oncol. 2011 Jan;6(1):209-17
pubmed: 21107292
Clin Cancer Res. 2016 Jun 15;22(12):3005-15
pubmed: 26763251
Blood. 2007 Dec 15;110(13):4319-30
pubmed: 17848619
JAMA Oncol. 2017 Dec 1;3(12):e173290
pubmed: 29049607
Adv Exp Med Biol. 2020;1234:15-29
pubmed: 32040852
Int J Gynecol Cancer. 2016 May;26(4):671-9
pubmed: 26905331
Cancers (Basel). 2021 Dec 01;13(23):
pubmed: 34885169
Cancers (Basel). 2019 Oct 21;11(10):
pubmed: 31640297
Oncotarget. 2017 Feb 28;8(9):15621-15631
pubmed: 28152503
Nat Commun. 2019 Nov 27;10(1):5408
pubmed: 31776331
Cancer. 2009 Jul 1;115(13):2891-902
pubmed: 19472394
Ther Adv Med Oncol. 2019 May 13;11:1758835919848872
pubmed: 31205506
Front Oncol. 2020 Feb 25;10:188
pubmed: 32161718
CA Cancer J Clin. 2019 Jul;69(4):280-304
pubmed: 31099893
Cancers (Basel). 2021 Apr 27;13(9):
pubmed: 33925671
Clin Cancer Res. 2013 Jul 1;19(13):3474-84
pubmed: 23633455
Methods Mol Biol. 2016;1403:755-61
pubmed: 27076165
EJC Suppl. 2020 Aug 22;15:56-66
pubmed: 33240443
Curr Biol. 2020 Aug 17;30(16):R921-R925
pubmed: 32810447
Nat Med. 2008 Jan;14(1):28-36
pubmed: 18157142
Thorac Surg Clin. 2019 May;29(2):123-131
pubmed: 30927993
Cancer Res. 2013 Jan 1;73(1):119-27
pubmed: 23108141
Front Immunol. 2020 Oct 06;11:577869
pubmed: 33123161
Clin Transl Oncol. 2009 Sep;11(9):564-71
pubmed: 19775995
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
Cancer Immunol Immunother. 2009 Mar;58(3):449-59
pubmed: 18791714
Eur J Pharm Sci. 2009 Nov 5;38(4):283-90
pubmed: 19733657
Cancers (Basel). 2019 Apr 11;11(4):
pubmed: 30979057
Nat Cell Biol. 2015 Feb;17(2):183-94
pubmed: 25621950
Front Oncol. 2017 Feb 22;7:24
pubmed: 28275576
Nat Rev Drug Discov. 2016 Jun 1;15(6):373-4
pubmed: 27245386
Cell Mol Life Sci. 2018 Feb;75(4):689-713
pubmed: 29032503
Br J Cancer. 2009 Nov 3;101(9):1513-21
pubmed: 19861998
Cancer Immunol Immunother. 2010 Feb;59(2):279-91
pubmed: 19727719
Oncotarget. 2018 Apr 3;9(25):17501-17511
pubmed: 29707124
Oncologist. 2015 Jul;20(7):812-22
pubmed: 26069281
Oncology. 2005;69 Suppl 3:4-10
pubmed: 16301830
Int J Mol Sci. 2022 Jan 27;23(3):
pubmed: 35163380
J Clin Diagn Res. 2017 Apr;11(4):EC43-EC46
pubmed: 28571149
Oncoimmunology. 2013 Sep 1;2(9):e25962
pubmed: 24327938
Front Oncol. 2022 May 12;12:877369
pubmed: 35646692
Clin Cancer Res. 2014 Jan 15;20(2):434-44
pubmed: 24190978
Front Oncol. 2013 Sep 25;3:256
pubmed: 24093089
PLoS One. 2014 Nov 03;9(11):e111757
pubmed: 25365237
Hum Vaccin Immunother. 2019;15(5):1111-1122
pubmed: 30888929
Gynecol Oncol. 2018 Nov;151(2):306-310
pubmed: 30194007
Am J Surg Pathol. 2012 Aug;36(8):1170-7
pubmed: 22790858
Cells. 2020 May 22;9(5):
pubmed: 32456078
Gynecol Oncol. 2019 May;153(2):217-222
pubmed: 30803719
Cell Immunol. 2019 Sep;343:103753
pubmed: 29395859
Int J Cancer. 2014 Jan 1;134(1):32-42
pubmed: 23784932
Mod Pathol. 2012 Apr;25(4):625-36
pubmed: 22193042
J Clin Invest. 2021 Feb 1;131(3):
pubmed: 33295887
Nat Rev Cancer. 2017 May;17(5):302-317
pubmed: 28303905
Immunotherapy. 2011 Apr;3(4):539-56
pubmed: 21463194
Int J Cancer. 2018 Jul 1;143(1):8-15
pubmed: 29218796
J Exp Med. 2015 Feb 9;212(2):139-48
pubmed: 25601652
PLoS One. 2009 Jul 29;4(7):e6412
pubmed: 19641607
Transl Oncol. 2022 Jan;15(1):101298
pubmed: 34875483
Genes Dev. 2014 Feb 15;28(4):305-16
pubmed: 24532711
Mod Pathol. 2009 Mar;22(3):393-402
pubmed: 19060844
Int J Mol Sci. 2018 Apr 26;19(5):
pubmed: 29701666
Eur J Immunol. 2014 Jun;44(6):1814-22
pubmed: 24510590
Clin Cancer Res. 2012 Jun 15;18(12):3281-92
pubmed: 22553348
Ther Adv Med Oncol. 2020 Oct 31;12:1758835920967241
pubmed: 33193829
Am J Surg Pathol. 2012 Feb;36(2):163-72
pubmed: 22189970
J Pathol. 2012 Jun;227(2):136-45
pubmed: 22322968
Int J Biol Sci. 2022 Apr 24;18(7):3019-3033
pubmed: 35541919